Literature DB >> 12169235

Ventricular tachycardia in structurally normal hearts.

T Scott Wall1, Roger A Freedman.   

Abstract

This review focuses on four distinct syndromes of ventricular tachycardia that occur in the structurally normal heart. Recent advances in the fields of molecular biology and genetics, along with intracardiac mapping techniques, have led to a greater understanding of the underlying mechanisms of and therapeutic options for these syndromes. The cyclic AMP-mediated triggered activity tachycardias, including exercise-induced right ventricular outflow track tachycardia and repetitive monomorphic ventricular tachycardia, are the most common of these syndromes. Idiopathic left ventricular tachycardia, for which there is significant evidence for re-entry within the Purkinje network, is largely curable with catheter ablation. The long QT syndrome comprises a heterogeneous group of ion channel defects leading to prolongation of myocyte repolarization and Torsade de Pointes ventricular tachycardia. Brugada syndrome, a familial disorder of transmembrane ion transport, is felt to be the result of a group of sodium channel defects leading to characteristic electrocardiographic abnormalities, and syncope and sudden death. Primary focus is given to recent advances in our understanding of the underlying mechanism and current therapeutic approaches.

Entities:  

Mesh:

Year:  2002        PMID: 12169235     DOI: 10.1007/s11886-002-0038-0

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  49 in total

Review 1.  The Brugada syndrome.

Authors:  Gerald V Naccarelli; Charles Antzelevitch; Deborah L Wolbrette; Jerry C Luck
Journal:  Curr Opin Cardiol       Date:  2002-01       Impact factor: 2.161

2.  Demonstration of the reentrant circuit of verapamil-sensitive idiopathic left ventricular tachycardia: direct evidence for macroreentry as the underlying mechanism.

Authors:  M Maruyama; T Tadera; S Miyamoto; T Ino
Journal:  J Cardiovasc Electrophysiol       Date:  2001-08

3.  Treatment of torsade de pointes with magnesium sulfate.

Authors:  D Tzivoni; S Banai; C Schuger; J Benhorin; A Keren; S Gottlieb; S Stern
Journal:  Circulation       Date:  1988-02       Impact factor: 29.690

4.  Long-term results of catheter ablation of idiopathic right ventricular tachycardia.

Authors:  F Morady; A H Kadish; L DiCarlo; W H Kou; S Winston; M deBuitlier; H Calkins; S Rosenheck; J Sousa
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

Review 5.  Ventricular arrhythmias in normal hearts.

Authors:  B B Lerman; K M Stein; S M Markowitz; S Mittal; D J Slotwiner
Journal:  Cardiol Clin       Date:  2000-05       Impact factor: 2.213

6.  Adenosine-sensitive ventricular tachycardia: right ventricular abnormalities delineated by magnetic resonance imaging.

Authors:  S M Markowitz; B L Litvak; E A Ramirez de Arellano; J A Markisz; K M Stein; B B Lerman
Journal:  Circulation       Date:  1997-08-19       Impact factor: 29.690

7.  Significance of morphological abnormalities detected by MRI in patients undergoing successful ablation of right ventricular outflow tract tachycardia.

Authors:  S Globits; G Kreiner; H Frank; G Heinz; U Klaar; B Frey; H Gössinger
Journal:  Circulation       Date:  1997-10-21       Impact factor: 29.690

8.  A structural basis for drug-induced long QT syndrome.

Authors:  J S Mitcheson; J Chen; M Lin; C Culberson; M C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

9.  Prevalence of the Brugada sign in idiopathic ventricular fibrillation and healthy controls.

Authors:  S Viskin; R Fish; M Eldar; D Zeltser; M D Lesh; A Glick; B Belhassen
Journal:  Heart       Date:  2000-07       Impact factor: 5.994

10.  Radiofrequency catheter ablation of idiopathic left ventricular tachycardia guided by a Purkinje potential.

Authors:  H Nakagawa; K J Beckman; J H McClelland; X Wang; M Arruda; I Santoro; H A Hazlitt; I Abdalla; A Singh; H Gossinger
Journal:  Circulation       Date:  1993-12       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.